EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer

Riccardo Laudicella iD, Matteo Bauckneht iD, Irene A Burger iD, Alberto Cacciola, Stefano Fanti, Andrea Farolfi iD, Vincenzo Ficarra, Andrei Iagaru, Virginia Liberini iD, Stefano Pergolizzi, Giulia Santo, Irene Virgolini und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025-06 · 52 (7) · 2723-2735

DOI: 10.1007/s00259-025-07083-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 12.02.2025. Verfasst von Riccardo Laudicella und 13 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Antigens, Surface, Radiopharmaceuticals. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Zurich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Conventional systemic therapies are valuable options in prostate cancer (PCa); however, such treatments can determine adverse events and toxicity. The observed improvement in overall survival, coupled with PSA reduction and a favorable safety profile in the post-taxane castration-resistant PCa (CRPC) setting has prompted the consideration of PSMA-based radioligand therapy (RLT) earlier in the treatment sequence. In this review, we will describe the literature and ongoing clinical trials regarding the use of PSMA-based RLT in hormone-sensitive PCa (HSPC) including the neoadjuvant, de-novo/synchronous metastatic, adjuvant, and early BCR settings.

Methods

We performed a systematic literature search on the PubMed/MEDLINE/EMBASE and clinicaltrials.gov databases for studies and protocols assessing the role of PSMA-based RLT in HSPC.

Results

The literature search yielded 140 results. After screening titles and abstracts and applying inclusion and exclusion criteria, we selected 25 papers showing the potentialities of earlier RLT in HSPC, with several ongoing trials.

Conclusion

Early use of PSMA-based RLT holds significant potential in HSPC patients from the neoadjuvant to the BCR setting. In these stages, the lower tumor burden, more frequent exclusive nodal involvement, and higher organ reserve may improve treatment efficacy and allow for treatment combinations while maintaining a less toxic profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGlutamate Carboxypeptidase IIAntigens, SurfaceRadiopharmaceuticalsHumansMaleLigands

Stichwörter der Autor:innen

HSPCPCaProstate-specific membrane antigenRLTTheranostics

Substanzen

Glutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, humanLigandsRadiopharmaceuticals

Autor:innen und Institutionen

  • Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy.
  • IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Nuclear Medicine, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.
  • Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Zurich, Switzerland. irene.burger@ksb.ch.
  • Department of Nuclear Medicine, Cantonal Hospital Baden, affiliated Hospital for Research and Teaching, University of Zurich, Baden, Switzerland. irene.burger@ksb.ch.
  • Brain Mapping Lab, Department of Biomedical, Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.

ORCID-Profile: Riccardo Laudicella, Matteo Bauckneht, Irene A Burger, Andrea Farolfi, Virginia Liberini

Förderung

  • University of Zurich

Zitieren

APA

Laudicella, R., Bauckneht, M., Burger, I. A., Cacciola, A., Fanti, S., Farolfi, A., Ficarra, V., Iagaru, A., Liberini, V., Pergolizzi, S., Santo, G., Virgolini, I., Minutoli, F., & Baldari, S. (2025). The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 52(7), 2723-2735. https://doi.org/10.1007/s00259-025-07083-8

Vancouver

Laudicella R, Bauckneht M, Burger IA, Cacciola A, Fanti S, Farolfi A, et al. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(7):2723-2735. doi:10.1007/s00259-025-07083-8

BibTeX
@article{Laudicella2025,
  author = {Laudicella, Riccardo and Bauckneht, Matteo and Burger, Irene A and Cacciola, Alberto and Fanti, Stefano and Farolfi, Andrea and Ficarra, Vincenzo and Iagaru, Andrei and Liberini, Virginia and Pergolizzi, Stefano and Santo, Giulia and Virgolini, Irene and Minutoli, Fabio and Baldari, Sergio},
  title = {The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {7},
  pages = {2723--2735},
  doi = {10.1007/s00259-025-07083-8}
}
Kostenlos starten →